Updated vaccine provides strong immune response against previous and emerging SARS-CoV-2 variants

New research using live SARS-CoV-2 virus reveals an updated vaccine provides a strong immune response against previous strains and emerging variants.

The findings by researchers at Oregon Health & Science University, published in the journal Emerging Infectious Diseases, suggest a clear benefit in receiving updated vaccinations on a regular basis, especially among older people or those with underlying medical conditions.

The virus is still circulating, it's continuing to evolve, and it remains dangerous. Sooner or later, there will be another variant that evades the immunity we have already built up. Our study demonstrates that it's worthwhile to update our immune repertoire."

Fikadu Tafesse, Ph.D., co-senior author, associate professor of molecular microbiology and immunology, OHSU School of Medicine

As the pandemic has receded from public consciousness, vaccine uptake has waned in the U.S., according to federal data.

The new study is the latest in laboratory research at OHSU testing variants of the SARS-CoV-2 virus. The project relies upon more than 2,000 university employees who have volunteered to have their blood drawn before, during and after vaccination. The research project began early in the pandemic with antibody testing.

In the latest study, researchers isolated blood drawn from 55 people before and after they received an updated vaccine beginning last fall that targets the XBB.1.5 subvariant of the omicron variant of the virus.

They found a strong response in terms of the levels of antibodies generated, and their ability to neutralize the original strain of SARS-CoV-2 plus new variants that have emerged since the novel coronavirus arrived in late 2019. Importantly, the vaccine appeared to generate a strong response against the JN.1 variant that is now circulating broadly worldwide – suggesting regularly updating the vaccine will be useful in confronting emerging variants.

The study marks another milepost in the evolution of the SARS-CoV-2 virus.

"Overall, this work strongly supports use of the updated vaccine," said co-senior author Marcel Curlin, M.D., associate professor of medicine (infectious diseases) in the OHSU School of Medicine and medical director of OHSU Occupational Health. "In the big picture, COVID-19 is not going away but lining up alongside the other common respiratory illnesses such as flu and RSV, which cause relatively mild disease for most people and a lot of harm to a few."

In contrast to most other research studies, OHSU is among the first to test the ability of vaccine-elicited antibodies in blood serum to block infection of a live virus in a biosafety level 3 laboratory.

In addition to Tafesse and Curlin, co-authors include Xammy Huu Nguyenla, Mastura Wahedi, Timothy Bates and Mila Trank-Greene of OHSU.

Source:
Journal reference:

Nguyenla, X. H., et al. (2024). Evaluating Humoral Immunity Elicited by XBB.1.5 Monovalent COVID-19 Vaccine. Emerging Infectious Diseases. doi.org/10.3201/eid3006.240051.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Increased emotional sensitivity linked to previous COVID-19 infection, new research suggests